Cargando…
A Response To: Sodium–Glucose Cotransporter 2 Inhibitors and Major COVID-19 Outcomes: Promising Mechanisms, Conflicting Data, and Intriguing Clinical Decisions
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer Healthcare
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7556550/ https://www.ncbi.nlm.nih.gov/pubmed/33052537 http://dx.doi.org/10.1007/s13300-020-00943-6 |
| _version_ | 1783594242510159872 |
|---|---|
| author | Bossi, Antonio C. Forloni, Franco Colombelli, Paolo L. |
| author_facet | Bossi, Antonio C. Forloni, Franco Colombelli, Paolo L. |
| author_sort | Bossi, Antonio C. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-7556550 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2020 |
| publisher | Springer Healthcare |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-75565502020-10-15 A Response To: Sodium–Glucose Cotransporter 2 Inhibitors and Major COVID-19 Outcomes: Promising Mechanisms, Conflicting Data, and Intriguing Clinical Decisions Bossi, Antonio C. Forloni, Franco Colombelli, Paolo L. Diabetes Ther Letter Springer Healthcare 2020-10-14 2020-12 /pmc/articles/PMC7556550/ /pubmed/33052537 http://dx.doi.org/10.1007/s13300-020-00943-6 Text en © The Author(s) 2020 Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/. |
| spellingShingle | Letter Bossi, Antonio C. Forloni, Franco Colombelli, Paolo L. A Response To: Sodium–Glucose Cotransporter 2 Inhibitors and Major COVID-19 Outcomes: Promising Mechanisms, Conflicting Data, and Intriguing Clinical Decisions |
| title | A Response To: Sodium–Glucose Cotransporter 2 Inhibitors and Major COVID-19 Outcomes: Promising Mechanisms, Conflicting Data, and Intriguing Clinical Decisions |
| title_full | A Response To: Sodium–Glucose Cotransporter 2 Inhibitors and Major COVID-19 Outcomes: Promising Mechanisms, Conflicting Data, and Intriguing Clinical Decisions |
| title_fullStr | A Response To: Sodium–Glucose Cotransporter 2 Inhibitors and Major COVID-19 Outcomes: Promising Mechanisms, Conflicting Data, and Intriguing Clinical Decisions |
| title_full_unstemmed | A Response To: Sodium–Glucose Cotransporter 2 Inhibitors and Major COVID-19 Outcomes: Promising Mechanisms, Conflicting Data, and Intriguing Clinical Decisions |
| title_short | A Response To: Sodium–Glucose Cotransporter 2 Inhibitors and Major COVID-19 Outcomes: Promising Mechanisms, Conflicting Data, and Intriguing Clinical Decisions |
| title_sort | response to: sodium–glucose cotransporter 2 inhibitors and major covid-19 outcomes: promising mechanisms, conflicting data, and intriguing clinical decisions |
| topic | Letter |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7556550/ https://www.ncbi.nlm.nih.gov/pubmed/33052537 http://dx.doi.org/10.1007/s13300-020-00943-6 |
| work_keys_str_mv | AT bossiantonioc aresponsetosodiumglucosecotransporter2inhibitorsandmajorcovid19outcomespromisingmechanismsconflictingdataandintriguingclinicaldecisions AT forlonifranco aresponsetosodiumglucosecotransporter2inhibitorsandmajorcovid19outcomespromisingmechanismsconflictingdataandintriguingclinicaldecisions AT colombellipaolol aresponsetosodiumglucosecotransporter2inhibitorsandmajorcovid19outcomespromisingmechanismsconflictingdataandintriguingclinicaldecisions AT bossiantonioc responsetosodiumglucosecotransporter2inhibitorsandmajorcovid19outcomespromisingmechanismsconflictingdataandintriguingclinicaldecisions AT forlonifranco responsetosodiumglucosecotransporter2inhibitorsandmajorcovid19outcomespromisingmechanismsconflictingdataandintriguingclinicaldecisions AT colombellipaolol responsetosodiumglucosecotransporter2inhibitorsandmajorcovid19outcomespromisingmechanismsconflictingdataandintriguingclinicaldecisions |